Aspira Women's Health (AWHL) AI Stock Analysis

• Market Cap: $5.18M
• Dividend Yield: N/A
• Average Volume (3M): 151.17K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.27
• Revenue Growth: 3.53%
• EPS Growth: 52.86%
• Country: US
• Employees: 66
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.09
• Shares Outstanding: 30,153,925
• 10 Day Avg. Volume: 85,832
• 30 Day Avg. Volume: 151,169
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: $0.00 ▼(-100.00%Downside)

Aspira Women's Health faces significant financial instability with negative equity and cash flow deficits. Despite some technical momentum, the stock's high volatility and negative valuation metrics pose substantial risks. The recent termination of a significant contract further highlights potential challenges in business strategy.

Aspira Women's Health Business Overview & Revenue Model

Company Description

Aspira Women's Health (AWHL) is a healthcare company focused on developing innovative diagnostic tests for gynecologic diseases, including ovarian cancer. Leveraging proprietary bioinformatics and a deep understanding of women's health, Aspira Women's Health aims to improve early detection and management of diseases affecting women. The company's core products include OVA1 and OVERA, which are blood-based tests that assess the risk of ovarian cancer in women with an adnexal mass.

How the Company Makes Money

Aspira Women's Health generates revenue primarily through the sale of its proprietary diagnostic tests, OVA1 and OVERA. These tests are marketed to healthcare providers and hospitals, who utilize them to assess the risk of ovarian cancer in patients. The company may also earn income through partnerships with other healthcare organizations and research institutions that leverage its bioinformatics capabilities. Additionally, Aspira Women's Health might explore avenues such as licensing its technology to expand its reach and applications in the women's health sector.

Aspira Women's Health Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Aspira Women's Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.17
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AWHL, the sentiment is Positive. The current price of 0.17 is above the 20-day moving average (MA) of 0.14, above the 50-day MA of 0.10, and below the 200-day MA of 0.43, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 71.36 is Negative, neither overbought nor oversold. The STOCH value of 89.73 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AWHL.

Aspira Women's Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ENZB	57 Neutral	$35.86M	―	-13.95%	―	―	―
ENZB	57 Neutral	$35.86M	―	-13.95%	―	―	―
Sector *	52 Neutral	$7.53B	0.32	-61.76%	2.28%	16.60%	1.56%
VNRX	49 Neutral	$76.24M	―	138.92%	―	64.15%	41.65%
VNRX	49 Neutral	$76.24M	―	138.92%	―	64.15%	41.65%
INBS	48 Neutral	$12.30M	―	-126.34%	―	3.87%	91.76%
INBS	48 Neutral	$12.30M	―	-126.34%	―	3.87%	91.76%
SERA	47 Neutral	$93.81M	―	-41.36%	―	-44.17%	12.77%
SERA	47 Neutral	$93.81M	―	-41.36%	―	-44.17%	12.77%
AWHL	42 Neutral	$5.18M	―		―	3.53%	52.86%
BDSX	42 Neutral	$39.81M	―	-1454.41%	―	35.76%	47.48%
BDSX	42 Neutral	$39.81M	―	-1454.41%	―	35.76%	47.48%

Aspira Women's Health Corporate Events

Aspira Women’s Health Ends ARPA-H Contract

On June 11, 2025, Aspira Women’s Health announced the termination of its contract with the Advanced Research Projects Agency for Health (ARPA-H) for the Sprint for Women’s Health initiative. Despite receiving $3.5 million of the $10 million award, ARPA-H determined that Aspira did not meet the specifications of Milestone 3, leading to the contract’s termination. Aspira’s CEO expressed confidence in the company’s progress and commitment to continue developing the ENDOinform test, which aims to improve the diagnosis and treatment of endometriosis, with a target completion in 2026.

The most recent analyst rating on (AWHL) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Aspira Women’s Health stock, see the AWHL Stock Forecast page.

Aspira Women’s Health Holds Annual Stockholder Meeting

On June 4, 2025, Aspira Women’s Health Inc. held its annual meeting of stockholders, where several key proposals were voted on. The stockholders elected six directors for a one-year term, approved executive compensation, the issuance of warrants, an amendment to the 2019 Stock Incentive Plan, and ratified the selection of BDO USA, LLP as the independent registered public accounting firm for 2025. These decisions reflect the company’s ongoing efforts to strengthen its governance and financial strategies, potentially impacting its market positioning and stakeholder confidence.

The most recent analyst rating on (AWHL) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Aspira Women’s Health stock, see the AWHL Stock Forecast page.